Elite Pharmaceuticals Inc (ELTP)

[WeeZuhl]

Q1: What does the noise of today have to do with Elite’s future?
A1: Nothing. What follows is meant to help enlighten investors.

Since nothing in the entire dissertation addresses anything I've said over the past 2 days, I'm not sure what this Q&A is meant to address (or when). It's not any of the points I've brought up. (Shareholder Rights Agreement of 2013?? Really????) But please, don't hesitate to eventually address some of this stuff. There is still plenty more to talk about, and such a milquetoast response was a real disappointment, tbh. A more spirited discussion would be helpful for all.


Now let's work and try to recover something instructive from this gross verbosity. Ah, yes, here's something:

Q2: What was the improvement of revenues YOY?
A2: The move was from $7.5 M to $18 M.

ELTP BOARD POLL QUESTION
Annual revenue in FY2020 was 18M, but what should it have been?

Reply with your response. What if Nasrat had commercialized each of the opioid ANDA's as they were approved? What if all 5 opioids had full year sales?

Percocet... approved 7/18... $500M... 16 competitors
Norco... approved 11/18... $447M... 11 competitors
Tyl w codeine...approved 9/19... $45M... 8 competitors
Methadone... approved 8/18... $30M... 10 competitors
hydromorphone... approved 1/12... $30M... 8 competitors

*Note: annual sales numbers are from Elite's PR. # of competitors is current as of July 2020.

**Bonus points: what was total development cost, in millions of dollars, of the 4 opioid ANDA's that were approved in 2018-2019?